Fourteen patients with chromomycosis have been treated orally with thiabendazole, either alone or in combination with surgery. Apparent cures have been obtained in five according to the criteria considered mandatory. The drug is well tolerated in the majority of cases with only minor symptoms of nausea and headache occurring at higher dosage levels. A hypersensitivity reaction, not previously recorded, developed in several patients, manifested by elevated serum bilirubin and transaminase values. The need for regular laboratory investigations is stressed. The problems and consequences of surgical intervention, including biopsies, may be due to the role of trauma in reactivating the infection. It is concluded that, at present, thiabendazole warrants a definite place in the treatment of chromomycosis.
Bayles MAH. Chromomycosis: Treatment With Thiabendazole. Arch Dermatol. 1971;104(5):476–485. doi:10.1001/archderm.1971.04000230018003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: